B.Y. Quantitative Medicine Limited

BYQM successes 40-year+ solid basic science discoveries; “Nucleolus is the origin of cancer” by Prof. Harris Busch (Baylor College of Medicine), “Good science always comes from a simple and important question” by Prof. Arthur Kornberg (A Nobel Laureate 1959, Stanford U), and the Nucleolar phosphoprotein (NPM1) which is a most important gene in regulating tumor growth or suppression (Prof. Ben Yung, Founder of BYQM).

We have analyzed the human genomic cellular 20,000 gene expression profiles from hundreds of Gene Expression Omnibus (GEO) datasets with big data tools, examined every biological process, and constructed the NPM1/B23 associated Gene Gene Co-expressions platform that reveals the patient’s comprehensive and precise pathology and biochemistry of his/her illness (multiple origins)”

We are the first company to establish a quantitative biochemistry platform for the analysis of gene gene co-expressions. Our self-developed deep learning service model provides a comprehensive and structural strategy to determine the gene gene co-expressions network of cancers and other diseases related to Nucleophosmin (NPM1/B23). This model provides important data for health assessment, disease diagnosis, prognosis and treatment, and for related drug development.

“Our core technology is built upon big data science to unravel the microscopic and macroscopic interconnected Gene Gene co-expressions networks in cancers, which will lead to quantitative, precision, and personalized medicine uncovering the origins of cancer and will bring new insights to the more precise diagnosis, selection of therapeutic regimen and pharmaceutical development to overcome cancer resistance, invasiveness, metastasis. BYQM’s Gene Gene Co-expressions Analysis leads us to Precision and Personalized Medicine for cancer and all diseases.”

My Sourcing

B.Y. Quantitative Medicine Limited

Unfollow this supplier?

Unfollow this supplier?